Search

A recent study conducted at Toho University Sakura Medical Center in Japan explored the predictive factors for macular edema recurrence in patients with branch retinal vein occlusion (BRVO) after treatment with intravitreal ranibizumab (IVR) injections. The researchers found that baseline choroidal blood flow (CBF) imbalance in the eyes of patients with BRVO may indicate a higher risk of macular edema recurrence following ranibizumab therapy. This study highlights the importance of monitoring CBF and choroidal thickness (CT) as potential predictors for disease progression in patients with BRVO. [Extracted from the article]

Researchers from Campus Bio-Medico University in Rome, Italy, have conducted a comprehensive review on the role of immune cells and signaling pathways in diabetic eye disease (DED). The study highlights the complex interactions between immune cells, inflammatory mediators, and signaling pathways that contribute to the development and progression of DED. The research aims to identify potential therapeutic targets and suggests directions for future studies to address the immunopathological aspects of DED, which are leading causes of visual impairments and blindness among working-age adults. The findings provide valuable insights into the pathophysiological mechanisms of DED and offer avenues for further research in this area. [Extracted from the article]

A recent study conducted at the University of Texas Southwestern Medical Center focused on the use of injectable intravitreal fluocinolone acetonide implant (FAI) for chronic postoperative cystoid macular edema (CME) in eyes with silicone oil-filled vitreous cavities. The research found that FAI could be beneficial in controlling chronic CME and may be considered for use in such cases, although further studies are needed to fully understand its pharmacokinetics and utility in silicone oil-filled vitreous cavities. The study concluded that the eye in question had no complications related to FAI treatment. [Extracted from the article]

A recent study conducted by researchers at the University of Toronto examined the clinical characteristics and outcomes of patients with non-infectious uveitis (NIU) who were treated with or without systemic immunomodulatory therapy (IMT). The study included 914 NIU patients, with a higher proportion of bilateral cases and chronic uveitis in the IMT group. Visual acuity improved significantly in both groups, with baseline visual acuity and panuveitis identified as predictors of final vision outcomes. This research provides valuable insights into the management and outcomes of NIU patients receiving different treatment approaches. [Extracted from the article]

A recent study conducted by the Ministry of National Guard Health Affairs focused on prophylactic regimens for preventing pseudophakic cystoid macular edema (PCME) following cataract surgery. The research evaluated the efficacy and safety of nonsteroidal anti-inflammatory drops (NSAIDs) and corticosteroids in reducing the incidence of PCME. Results indicated that NSAIDs, either alone or in combination with steroids, were effective in decreasing the risk of PCME post-operatively. Further randomized controlled trials are recommended to establish standardized protocols for different patient populations. [Extracted from the article]

A recent study conducted at Mataria Teaching Hospital in Cairo, Egypt, explored the use of topical bromfenac in combination with intravitreal ranibizumab injections for the treatment of diabetic macular edema (DME). The study, which included 40 eyes of patients with DME, found that the combination therapy showed some efficacy over a 6-month follow-up period, although the results were not statistically significant. The research highlighted the importance of evaluating adjunctive treatments for DME to improve patient outcomes. [Extracted from the article]

A recent study conducted at Shinshu University in Nagano, Japan, focused on the use of portable optical coherence tomography (OCT) in assessing diabetic macular edema (DME). The research aimed to evaluate the reliability of a portable OCT device compared to a traditional stationary OCT device in diagnosing and monitoring DME. The study found that the portable OCT device demonstrated high reliability for DME evaluations, making it a potentially valuable tool for early diagnosis and continuous monitoring of this condition. [Extracted from the article]

A recent study conducted by McMaster University School of Medicine compared the safety and efficacy of anti-VEGF monotherapy versus anti-VEGF and steroid combination therapy for diabetic macular edema (DME). The study included 16 randomized control trials with 1166 eyes, showing that monotherapy resulted in better visual acuity and smaller changes in retinal thickness compared to combination therapy. While both treatments had similar effects on visual acuity, combination therapy was associated with increased complications. The research suggests that most results were similar for treatment-naive and treatment-resistant patients. [Extracted from the article]

A patent has been issued for the use of dopamine and serotonin receptor antagonists in treating retinal degeneration in subjects. The patent aims to address the limited treatment options available for conditions such as retinitis pigmentosa and age-related macular degeneration, which can lead to blindness. The method involves administering specific compounds that block or diminish stimulation of these receptors, potentially offering new therapeutic approaches for patients with retinal degeneration. [Extracted from the article]

A study conducted by investigators from Amity University in Noida, India, introduced a novel guided-ensemble approach for automated diagnosis of retinal disorders using Optical Coherence Tomography images. The approach, which involved fine-tuning four pre-trained CNNs and combining their prediction scores, achieved an accuracy of 99.8% in classifying different types of retinal pathologies. The research, published in the International Journal of Imaging Systems and Technology, focused on detecting conditions like drusen, choroidal neovascularization, and diabetic macular edema to prevent vision loss. [Extracted from the article]

A recent study conducted at the University of Sao Paulo focused on the treatment of diabetic macular edema (DME) using a combination of laser techniques and intravitreal ranibizumab. The study found that the short pulse grid laser (SP) and subthreshold micropulse laser (MP) technique, along with intravitreal ranibizumab, led to significant improvements in central subfield thickness (CSFT), best-corrected visual acuity (BCVA), and macular sensitivity in patients with DME. The research concluded that this combined treatment approach was effective in addressing DME in patients. [Extracted from the article]

A recent study conducted at the Cleveland Clinic focused on predicting patient responses to lapses in anti-VEGF treatment for macular edema secondary to retinal vein occlusion. The research found that factors such as age, BMI, time since diagnosis, and history of dyslipidemia can influence the likelihood of vision loss after a treatment lapse. These findings can help healthcare providers counsel patients and determine appropriate follow-up schedules. The study was supported by a Research to Prevent Blindness Challenge Grant from the Cleveland Eye Bank Foundation and has been peer-reviewed. [Extracted from the article]

Researchers at the Institute of Clinical Neurosciences conducted a study on the use of intravitreal faricimab in treating neovascular age-related macular degeneration (nAMD) in treatment-naive patients. The study involved 21 eyes of 19 patients, with positive outcomes such as improved visual acuity and anatomical improvements over a median follow-up of 64.9 weeks. The research concluded that intravitreal faricimab showed favorable efficacy, safety, and durability in this real-world cohort of nAMD patients. [Extracted from the article]

A study conducted by Johns Hopkins University compared the efficacy and safety of MYL-1701P, an aflibercept biosimilar, with reference aflibercept in diabetic macular edema (DME). The study included participants from various countries and analyzed data from October to December 2021. The results showed that MYL-1701P demonstrated clinical equivalence to reference aflibercept in terms of efficacy, safety, and immunogenicity. These findings suggest that MYL-1701P could be used as an alternative to reference aflibercept. The research has been peer-reviewed and published in JAMA Ophthalmology. [Extracted from the article]

A new report from the University Hospital Zurich discusses the dynamics of treatment response to the first intravitreal faricimab injection in eyes with diabetic macular edema (DME). The study, conducted at the Department of Ophthalmology, included patients with treatment-naive and pretreated DME. The results showed that faricimab is an effective treatment for DME, with stable corrected visual acuity and a significant decrease in central subfield thickness after one month. The study also found no short-term safety concerns associated with the treatment. This research provides valuable insights into the use of faricimab for DME treatment. [Extracted from the article]

A recent study conducted in Switzerland evaluated the effectiveness of intravitreal dexamethasone (DEX) implant as a second-line treatment for diabetic macular edema (DME) patients who did not respond well to anti-vascular endothelial growth factor (anti-VEGF) therapy. The study analyzed data from 95 eyes of 89 patients and found that the addition of DEX to anti-VEGF therapy significantly reduced treatment burden and retinal fluid while maintaining visual function. The study suggests that treatment decisions for DME patients should consider individual patient needs and balance anatomical and functional outcomes. [Extracted from the article]

A study conducted in Vila Nova de Gaia, Portugal aimed to identify predictive factors for the improvement of visual acuity and reduction of central macular thickness in patients with macular edema due to branch retinal vein occlusion. The study included 161 eyes and found that visual acuity significantly improved and central macular thickness decreased during the 12-month follow-up period. Age at diagnosis and baseline visual acuity were identified as independent predictors of visual outcome. The study provides valuable information for the treatment of macular edema in patients with branch retinal vein occlusion. [Extracted from the article]

A recent study conducted by Southeast University evaluated the effectiveness and safety of the intravitreal dexamethasone implant in patients with diabetic macular edema (DME). The study found that the implant improved both anatomical and functional outcomes in both naive and refractory eyes, with naive eyes showing better visual outcomes. The study also concluded that the dexamethasone implant is a viable first-line therapy for naive eyes. The research provides further evidence for the use of dexamethasone implants in treating DME. [Extracted from the article]

A study conducted by researchers at Sapienza University of Rome explored the effects of intravitreal dexamethasone (IVD) on the choroidal vascularity index (CVI) in patients with diabetic macular edema (DME). The study found that there were no significant changes in CVI, luminal area, stromal area, and total area in the overall patient sample after IVD treatment. However, responder patients did experience a reduction in CVI at 4 months. The researchers suggest that CVI could potentially serve as a biomarker for treatment response in DME, but further studies are needed to confirm these findings. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the potential use of VIAN-c4551, a cyclic antiangiogenic peptide, as a non-invasive treatment for diabetic macular edema and diabetic retinopathy. The abstract highlights that VIAN-c4551 eye drops demonstrated high potency in inhibiting vascular endothelial cell growth factor (VEGF) and preventing retinal vascular leakage induced by VEGF. The eye drops also showed high permeability and reached therapeutic concentrations in the back of the eye. The researchers suggest that VIAN-c4551 eye drops could be a once-a-day, non-invasive intervention for preventing and reversing retinal vascular leakage in various vascular retinopathies. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A recent study conducted by the University of Texas Medical Branch examined the use of anti-vascular endothelial growth factor (VEGF) injections for the treatment of diabetic macular edema (DME). The study found that a protocol of three monthly injections on a pro re nata (PRN) basis resulted in improved vision and reduced macular thickness in over 85% of patients over a 24-month period. The number of injections and visits were identified as important factors in improving vision. This research provides valuable insights into the treatment of DME and may be of interest to individuals researching eye diseases and conditions. [Extracted from the article]

A recent report from the University of Texas Austin discusses a case study of a pediatric patient with Coats plus syndrome, a rare and life-threatening condition that affects the retina, central nervous system, and gastrointestinal system. The patient initially presented with symptoms resembling familial exudative vitreoretinopathy (FEVR), but genetic analysis revealed mutations associated with Coats plus syndrome. The patient's cystoid macular edema (CME) was successfully treated with systemic bevacizumab, resulting in significant improvement. This research provides valuable insights into the management of macular edema in patients with Coats plus syndrome. [Extracted from the article]

Researchers at Jilin University in the People's Republic of China have reported new data on the joint grading of diabetic retinopathy (DR) and diabetic macular edema (DME) using an adaptive attention block and semisupervised learning. The study emphasizes the importance of early screening and treatment for these conditions to prevent blindness in diabetic patients. The researchers propose an adaptive attention block (AAB) to improve model performance and a lightweight architecture called AABNet for grading prediction. Their experiments show that AABNet outperforms other methods in multiple grading tasks. This research has been peer-reviewed and published in Applied Intelligence. [Extracted from the article]

A recent study conducted by researchers at the University of Arkansas for Medical Sciences investigated the development of cystoid macular edema (CME) following the use of silicone oil (SO) in pars plana vitrectomy (PPV) surgeries for retinal detachment. The study included 43 eyes from 40 patients who underwent SO tamponade for retinal detachment surgery. The researchers found that a scleral buckle procedure and poor initial vision were significant factors for predicting the development of CME. Overall, 41.9% of patients developed CME with an average duration of 9 months. The findings highlight the importance of early monitoring and prompt management of CME in these surgeries. [Extracted from the article]

A recent study conducted by researchers at Florida State University College of Medicine explores the spontaneous closure of a chronic macular hole after unsuccessful surgical repair. The case study involves a 71-year-old woman who initially underwent surgical treatment for a full-thickness macular hole but experienced no improvement. However, after developing cystoid macular edema (CME) secondary to acute iritis, the macular hole unexpectedly closed. The researchers suggest that clinicians should consider the potential role of CME in managing chronic macular holes that do not respond to primary surgical repair. [Extracted from the article]

A study conducted at Sarasota Memorial Hospital in Florida has found that a single intravitreal fluocinolone 0.18-mg implant can effectively and safely treat chronic postoperative cystoid macular edema (CME) associated with noninfectious posterior uveitis. CME is a common cause of postoperative visual loss and can occur after intraocular surgery. The conventional approaches to managing chronic postoperative CME have limitations, such as the need for repeated dosing. The fluocinolone implant provides a long-acting, low-dose anti-inflammatory treatment for patients with this condition. Two case reports showed significant improvement in visual acuity and reduction in macular edema after treatment with the implant. [Extracted from the article]

A research study conducted at Maharaja Agrasen Medical College in Haryana, India, has found that biosimilars of bevacizumab are safe, effective, and cost-effective in treating diabetic macular edema (DME). The study compared two biosimilars, BevaciRelTM and ZyBev, to the original medication Avastin in a randomized control study. The results showed similar improvements in visual acuity and a decrease in central retinal thickness across all groups. The study concluded that biosimilars of bevacizumab are a viable option for treating DME in a cost-effective manner. [Extracted from the article]

A report from Houston Methodist Hospital discusses the use of eye plaque brachytherapy (EPBT) as a treatment for locally recurrent uveal melanoma. The study included five patients who had previously been treated for uveal melanoma with EPBT and experienced local recurrence. The patients were re-irradiated with EPBT, and the results showed a 100% local control rate. While some patients experienced ocular toxicities such as worsening visual acuity and cataracts, none of them required enucleation. The study concludes that EPBT is a viable alternative to enucleation with a high local control rate. [Extracted from the article]

A recent report from Bern University Hospital in Switzerland discusses the use of personalized medicine in the treatment of retinal vein occlusion (RVO) associated macular edema (ME). RVO is a leading cause of vision loss, and ME is a common consequence of RVO that impairs vision. The study focuses on identifying biomarkers that can predict treatment response to corticosteroids in RVO-associated ME, using imaging techniques and cytokine assessments. The researchers suggest that early identification of these biomarkers can guide personalized treatment decisions and improve outcomes for patients. They also mention the potential for advanced diagnostics and machine learning to further refine treatment strategies. [Extracted from the article]

A study conducted by Wenzhou Medical University investigated the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy on post-vitrectomy macular edema (PVME) in patients with proliferative diabetic retinopathy. The study included 179 patients who underwent surgery and developed PVME within 3 months after the procedure. The results showed that anti-VEGF treatment did not significantly improve visual acuity compared to no treatment. However, central retinal thickness decreased significantly in both groups. The study concluded that PVME tends to resolve spontaneously in the early postoperative period, and the effect of anti-VEGF therapy within the first 3 months appears to be limited. [Extracted from the article]

A recent study conducted at the University Hospital of Lyon in France provides practical guidelines for the use of fluocinolone acetonide (FAc) implant in the treatment of diabetic macular edema (DME). DME is a common complication of diabetic retinopathy. The study found that while intravitreal injections are effective, they can be burdensome for patients, necessitating the need for long-term treatments like the FAc implant. However, caution should be exercised as the implant has been associated with ocular hypertension and cataract. The objective of the study is to provide clinicians with guidelines on the introduction and use of the FAc implant in DME management. [Extracted from the article]

A patent has been issued to inventors from Johns Hopkins University for biomarkers that could be useful in the treatment of eye diseases such as retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy. The patent describes methods for assessing the severity of these diseases by measuring markers of oxidative stress in biological samples from patients. These biomarkers could also be used to monitor disease progression and determine the effectiveness of treatments. The inventors suggest that the identification and development of these biomarkers would be beneficial for planning and conducting clinical trials. [Extracted from the article]

A report by the American Academy of Ophthalmology, conducted by investigators at Flinders University, reviews the effectiveness and complications of periocular and intraocular corticosteroid therapies for noninfectious uveitic macular edema. The literature search yielded 739 citations, with 53 articles selected for inclusion. The assessment of these articles found that periocular and intraocular corticosteroid therapies consistently improved visual acuity and macular structure in patients with uveitic macular edema. However, information on the relative effectiveness and complication rates across different therapies is limited. The published literature provides high-quality evidence that these therapies are effective and safe for the treatment of noninfectious uveitic macular edema. [Extracted from the article]

A recent study conducted by Tsinghua University in Beijing, China, examined the efficacy, durability, and safety of a personalized treat-and-extend (T&E) regimen using faricimab for the treatment of diabetic macular edema (DME). The study found that faricimab, a dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibitor, demonstrated comparable results to aflibercept, another commonly used treatment. The personalized T&E-based dosing regimen with faricimab showed clinically meaningful visual acuity gains, anatomic improvements, and extended durability for patients with DME. The study concluded that faricimab has the potential to provide durable efficacy and promote vascular stability in DME patients. [Extracted from the article]

A new study conducted at Toulouse University Hospital in France has examined the prevalence of microcystic macular edema (MME) in patients with non-glaucomatous optic atrophy (OA). The study found that MME developed in 15% of the eyes included in the study, and its presence was associated with thinning of the ganglion cell layer and the retinal nerve fiber layer. Patients with MME also had worse visual acuity compared to those without MME. The study concludes that the presence of MME cannot be used to guide the diagnostic work-up of OA. [Extracted from the article]

A study conducted at the University of Bari 'Aldo Moro' in Italy has identified optical coherence tomography (OCT) biomarkers that are closely associated with long-term visual outcomes in individuals with macular edema resulting from retinal vein occlusion (RVO) who have undergone anti-vascular endothelial growth factor (anti-VEGF) therapy. The study found that changes in the status of the external limiting membrane and the presence of disorganization of the retinal inner layers serve as valuable OCT biomarkers, indicating prolonged visual outcomes in eyes where macular edema resulting from RVO has been successfully resolved with anti-VEGF therapy. These findings provide important insights for the diagnosis and treatment of RVO-related macular edema. [Extracted from the article]

A study conducted at Princess Nourah Bint Abdulrahman University in Riyadh, Saudi Arabia, assessed the adherence of clinicians to the instructions for using the immunosuppressive agent fingolimod. The study aimed to identify the consequences of poor adherence and highlight areas for improvement. The research found that physicians' adherence to the manufacturer's instructions was poor, resulting in a high rate of drug switching or discontinuation. Complications such as bradycardia, macular edema, infections, and elevated liver enzymes were reported in some patients. The study emphasizes the need for improved adherence to fingolimod instructions to ensure patient safety. [Extracted from the article]

A research study conducted by Sorbonne Paris Nord University in France examined the association between macular thickness fluctuations and visual acuity outcomes in eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone (DEX) implant. The study found that greater fluctuations in retinal thickness were linked to poorer visual outcomes in DME patients treated with the DEX implant. The researchers suggest that analyzing the standard deviation of macular thickness measurements could be a more predictive indicator of visual prognosis than individual measurements. This information may be useful for individuals researching macular edema and seeking to understand the potential effects of DEX implant treatment. [Extracted from the article]

A new study conducted by researchers from the School of Computer Science & Engineering focuses on the detection and classification of diabetic retinopathy (DR) and diabetic macular edema (DME), which are vision-related complications commonly found in diabetic patients. The study proposes an automatic approach that utilizes image processing techniques, such as Discrete Wavelet Transform (DWT), Artificial Neural Network (ANN) based segmentation, Adaptive Gabor Filter (AGF) for feature extraction, and Random Forest (RF) for feature selection. The approach also incorporates the use of Chicken Swarm Algorithm (CSA) to optimize the weights of the convolution and fully connected layers of the Deep Convolutional Neural Network (CNN) classifier. The proposed approach achieves an accuracy of 97.91% in determining the grades of DR/DME. [Extracted from the article]

A recent study conducted at Odense University Hospital in Denmark reviewed the real-world efficacy of faricimab, a novel anti-VEGF and anti-angiopoietin-2 bispecific agent, for the treatment of diabetic macular edema (DME). The study analyzed data from 10 eligible studies, which included a total of 6,054 eyes with a mean follow-up of 55 days to 12 months. The findings showed that faricimab improved visual acuity and macular thickness, and allowed for extended treatment intervals in a significant percentage of eyes. The study concluded that faricimab yields similar clinical outcomes to previous anti-VEGF treatments but with reduced treatment burden for patients. Further long-term real-world studies are recommended. [Extracted from the article]

A new study conducted by researchers at the Chicago School of Medicine explores the association between cigarette smoking and the development of diabetic macular edema (DME) in patients with diabetes. The study used claims data from patients across all 50 states in the United States from 2010 to 2020. After matching patients based on demographics and comorbidities, the study found that the cumulative risk for DME was significantly higher among never smokers compared to active smokers and former smokers. The researchers concluded that while the harms of smoking outweigh any potential protective benefits, further investigation into the mechanisms behind these findings could lead to new therapeutic targets. [Extracted from the article]

A newly launched clinical trial, NCT06583109, aims to establish a prediction model for the treatment efficacy of age-related macular degeneration (AMD) based on multi-source imaging modalities. AMD is a leading cause of blindness in the elderly population, and the main treatment method currently is intraocular injection of anti-VEGF drugs. However, patients have varying responses to this therapy, and some do not respond well in the short and long term. The study will analyze clinical and imaging data to construct feature models for predicting the prognosis of AMD patients and evaluate their clinical application value. The purpose of the study is to provide a scientific basis for early prediction, dynamic monitoring, and optimization of treatment strategies for AMD. [Extracted from the article]

A study conducted by the Japan Clinical REtina Study Group (J-CREST) and Nara Medical University investigated the incidence and prognosis of taxane-induced macular edema, a known side effect of taxane-based anticancer drugs. The study analyzed data from 11 centers between January 2016 and December 2021 and found that 0.21% of the 14,260 patients developed macular edema. Among these cases, the number associated with nab-paclitaxel was significantly higher than those associated with paclitaxel or docetaxel. The study also found that discontinuation of anticancer drugs led to significant improvement in visual acuity and edema. Regular ophthalmologic evaluation during treatment is recommended to monitor for macular edema. [Extracted from the article]

The article presents a new study from the Military Medical Academy that highlights the benefits of using topical bromfenac as an adjunct to anti-VEGF therapy for macular edema. Topics discussed include the effectiveness of topical non-steroidal anti-inflammatory drugs, the results of a systematic review and meta-analysis of relevant studies, and the potential for reducing treatment burden while maintaining visual acuity and central retinal thickness.

A patent application has been submitted for a new ophthalmic surgical instrument designed to peel retinal membranes without causing damage to the retina. The instrument includes a handpiece, an actuator, and a grasping structure with openings that can be connected to a vacuum pressure source. The grasping structure also features a blade and a cushion to facilitate the peeling process. The invention aims to reduce the risk of retinal damage during membrane removal procedures. [Extracted from the article]